Answers are grounded in this paper and cite their sources.
The landscape of neuromodulation therapy is changing rapidly.Accelerated transcranial magnetic stimulation (TMS) protocols now compress 6-week depression treatment courses into as little as 5 days.Exploratory studies of a single-day regimen have reported remission rates of 49-72% in treatment-resistant depression (TRD).Three converging principles define this shift: acceleration (compressing treatment from weeks to hours); augmentation (pharmacologically enhancing synaptic plasticity); and precision targeting (connectomeinformed, individualized site selection).This narrative review synthesizes evidence across all 3 domains, with an emphasis on studies published from 2022 to 2026.Key milestones include a second sham-controlled RCT confirming the efficacy of the SAINT/SNT (Stanford Accelerated Intelligent Neuromodulation Therapy) protocol and the first clinical description of a single-day TMS regimen (ONE-D (Optimized, Neuroplasticity-Enhanced techniques in Depression)) that leverages pharmacological augmentation with D-cycloserine (DCS) to enhance neuroplasticity.Precision strategies, including resting-state functional connectivity magnetic resonance imaging (fcMRI)-guided targeting, closedloop electroencephalography (EEG) systems, and emerging biomarkers, are increasingly complementing anatomical landmark-based methods.We devote particular attention to Parkinson's disease (PD), where the identification of the somato-cognitive action network (SCAN) as a key dysfunctional circuit illustrates how these principles translate into clinical efficacy.SCAN-targeted TMS approximately doubled the magnitude of motor improvement compared with conventional motor cortex stimulation.Finally, we review comparative effectiveness data positioning TMS alongside pharmacotherapy and esketamine, emerging health-economic evidence supporting its cost-effectiveness, and the challenges of scaling precision approaches for routine clinical care.This is a narrative review without a formal risk-of-bias assessment or meta-analytic pooling; limitations of this approach are discussed in the section "Limitations and translational challenges".
No takes yet. Share an insight, caveat, or question.
Wiener et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: